Results 61 to 70 of about 4,527,801 (246)

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity [PDF]

, 2005
When purified under rigorous conditions, some murine anti-double-stranded-DNA (anti-dsDNA) antibodies actually bind chromatin rather than dsDNA. This suggests that they may actually be antinucleosome antibodies that only appear to bind dsDNA when they ...
Lambrianides, A, Rahman, A, Anisur Rahman, Isenberg, DA, Mason, LJ, David S Latchman, Lesley J Mason, Manson, JJ, Latchman, DS, Jessica J Manson, David A Isenberg, Joanna D Haley, Haley, JD, Anastasia Lambrianides   +13 more
core   +1 more source

Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice [PDF]

, 2010
The motor axonal variant of Guillain-Barré syndrome is associated with anti-GD1a immunoglobulin antibodies, which are believed to be the pathogenic factor. In previous studies we have demonstrated the motor terminal to be a vulnerable site.
Halstead, S., Furukawa, K., Humphreys, P.D, Willison, H.J., McGonigal, R., Rowan, E.G., Greenshields, K.N, Rother, R.P   +7 more
core   +2 more sources

Development and validation of an ELISA-based method for determining neutralizing antibodies to pembrolizumab in human serum based on inhibition of the drug binding to its PD-1 target

Медицинская иммунология
Monoclonal antibodies (mAbs) are potentially able to trigger undesired humoral immune responses in the patients and develop ADA (anti-drug antibody) to the protein drugs.
A. M. Kudryashova, D. Yu. Grebenkin, M. Yu. Samsonov, O. V. Filon, V. A. Razzhivina, M. G. Chernobrovkin, O. V. Borisova   +6 more
doaj   +1 more source

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Designing of an ELISA Method for the Measurement of Serum Antibodies against Interferon-beta and the Study of the Frequency of these Antibodies in Patients with Multiple Sclerosis Treated with CinnoVex

مجله دانشکده پزشکی اصفهان, 2012
Background: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. Interferon-beta (IFN-β) was the first disease modifying drug to be approved for the treatment of MS.
Nasrin Zare, Sayyed Hamid Zarkesh Esfahani, Vahid Shaygannejad, Marjan Gharagozloo   +3 more
doaj  

Long-term time trends in reactivated herpes simplex infections and treatment in Sweden

BMC Infectious Diseases, 2022
Background Our aim was to describe the annual prevalence of herpes simplex virus (HSV) reactivation in relation to solar ultraviolet (UV) radiation and antiviral drug use in the Swedish adult population.
Karin Lopatko Lindman, Judith Lockman-Lundgren, Bodil Weidung, Jan Olsson, Fredrik Elgh, Hugo Lövheim   +5 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Evaluating the neutralizing antibody response to HIV-1 membrane proximal external regional; Implications for vaccine design [PDF]

, 2014
Includes bibliographical references.Inducing broadly neutralizing antibodies targeting the HIV-1 envelope is thought to be crucial for developing an effective vaccine.
Jacob, Rajesh Abraham
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source